

1 **Title: Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2 α -dependent**
2 **integrated stress response in C9orf72 FTD/ALS**

3
4 **Authors:** Janani Parameswaran¹, Nancy Zhang¹, Kadamawit Tilahun¹, Devesh C. Pant¹,
5 Ganesh Chilukuri¹, Seneshaw Asress², Anwasha Banerjee¹, Emma Davis¹, Samantha L.
6 Schwartz³, Graeme L. Conn³, Gary J. Bassell¹, Jie Jiang^{1*}

7
8 **Affiliations:**

9 ¹Department of Cell Biology, Emory University, Atlanta GA, 30322, USA. ²Department of
10 Neurology, Emory University, Atlanta, GA 30322, USA. ³Department of Biochemistry, Emory
11 University, Atlanta, GA 30322, USA

12
13 Correspondence should be addressed to Jie Jiang (jie.jiang@emory.edu)
14 Tel: +1404-727-1597; Fax: +1404-727-6256

15
16 **Abstract:**

17 GGGGCC (G₄C₂) hexanucleotide repeat expansion in the C9orf72 gene is the most common
18 genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The
19 repeat is bidirectionally transcribed and confers gain of toxicity. However, the underlying toxic
20 species is debated, and it is not clear whether antisense CCCC GG (C₄G₂) repeat expanded
21 RNAs contribute to disease pathogenesis. Our study shows that C9orf72 (C₄G₂) antisense
22 repeat expanded RNAs trigger the activation of the PKR/eIF2 α -dependent integrated stress
23 response independent of dipeptide repeat proteins that are produced through repeat-associated
24 non-AUG initiated translation, leading to global translation inhibition and stress granule
25 formation. Increased phosphorylation of PKR/eIF2 α is also observed in the frontal cortex of
26 C9orf72 FTD/ALS patients. Finally, only antisense (C₄G₂), but not sense (G₄C₂), repeat
27 expanded RNAs can activate the PKR/eIF2 α pathway. These results provide a mechanism by
28 which antisense repeat expanded RNAs elicit neuronal toxicity in FTD/ALS caused by C9orf72
29 repeat expansions.

30
31 **Keywords:** FTD/ALS, Antisense RNA, Sense RNA, Integrated stress response, PKR, Stress
32 granules

33
34
35 **Introduction**

36
37 In 2011, GGGGCC (G₄C₂) hexanucleotide repeat expansion in the first intron of chromosome
38 9 open reading frame 72 (C9orf72) gene was identified as the most common genetic cause of
39 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two
40 neurodegenerative diseases that are now believed to belong to a continuous disease spectrum

41 with clinical, pathological, and genetic overlaps [1, 2]. In normal populations, the G₄C₂ repeat
42 size is between two and thirty, whereas it expands to hundreds or thousands in FTD/ALS
43 patients (referred to hereafter as C9FTD/ALS). C9FTD/ALS thus joins an increasing number
44 of repeat expansion disorders including Huntington's disease, myotonic dystrophy, and several
45 spinocerebellar ataxias [3]. Based on initial pathological assessment of C9FTD/ALS patient
46 postmortem tissues and lessons learned from other repeat expansion disorders, several
47 pathogenic mechanisms by which expanded C9orf72 repeats can exert toxicity were proposed
48 [4]. First, expanded G₄C₂ repeats inhibit C9orf72 mRNA transcription, leading to
49 haploinsufficiency of C9orf72 protein [5, 6]; second, C9orf72 repeats are bidirectionally
50 transcribed into sense G₄C₂ and antisense CCCC GG (C₄G₂) RNAs. These repeat-expanded
51 RNAs may cause gain of toxicity by sequestering key RNA binding proteins into RNA foci
52 and/or by production of toxic dipeptide repeat (DPR) proteins via non-canonical repeat-
53 associated non-AUG-dependent (RAN) translation from all reading frames. More specifically,
54 translating from sense G₄C₂ RNAs produces GA (Glycine-Alanine), GP (Glycine-Proline), and
55 GR (Glycine-Arginine) DPR proteins, and translating from antisense C₄G₂ RNAs produces GP
56 (Glycine-Proline), PA (Proline-Alanine), and PR (Proline-Arginine) DPR proteins [7]. In
57 addition to these pure dimeric DPR proteins, there is also evidence of chimeric DPR proteins
58 both in vitro and in patients [8-10].

59
60 How C9orf72 repeat expansions cause FTD/ALS has been extensively explored. Although
61 reducing C9orf72 in zebrafish or *C. elegans* can cause motor deficits [11, 12], reduced or even
62 complete deletion of C9orf72 in mice does not lead to FTD/ALS-like abnormalities, suggesting
63 that loss of C9orf72 is not a main disease driver [13-19]. Supporting this, no missense or
64 truncation mutations in C9orf72 are found in FTD/ALS patients yet [20]. On the other hand,
65 several lines of studies, by expressing either G₄C₂ repeats [21, 22] or individual codon-
66 optimized, ATG-driven DPR proteins [23-25], support that gain of toxicity from repeat
67 expanded RNAs plays a central role in disease pathogenesis. Finally, loss of C9orf72, which
68 plays a role in autophagy/lysosomal functions, can exacerbate toxicity from the repeat
69 expanded RNAs [26, 27].

70
71 The underlying toxic species arising from C9orf72 repeat expanded RNAs that drive disease is
72 still debated. Several RNA binding proteins (RBPs) are suggested to interact with G₄C₂ or G₄C₂
73 repeat RNAs and co-localize with RNA foci [28-35]. However, strong evidence supporting that
74 loss of any proposed RBPs drives C9FTD/ALS is lacking. In contrast, ectopic expression of

75 individual DPR proteins, especially GR and PR, causes toxicity in various model systems [23-
76 25, 36-50]. To determine the relative contributions of RNA foci- and DPR protein- mediated
77 toxicity, two studies employed interrupted repeats with stop codons in all reading frames to
78 prevent DPR protein production and concluded that both sense and antisense RNAs are not
79 toxic in *Drosophila* [51, 52]. This was challenged by another study showing both sense and
80 antisense RNAs can cause motor axonopathy in zebrafish independent of DPR proteins [11].
81 Irrespective of RNA foci and DPR proteins, studies using antisense oligonucleotide (ASOs) to
82 selectively degrade sense G₄C₂ repeat expanded RNAs strongly support its role in C9FTD/ALS
83 pathogenesis. These sense strand-specific ASOs not only mitigate toxicity from C9orf72 repeat
84 expansions in both transgenic mice expressing G₄C₂ repeats [22] and iPSC-derived neurons
85 [28], but also reverse downstream cellular and molecular alterations such as nucleocytoplasmic
86 transport deficits [53]. However, whether antisense C₄G₂ expanded RNAs contribute to
87 C9FTD/ALS and thus are targets of intervention is less clear. Although PR translated from
88 antisense strand is extremely toxic in model systems, PR or its aggregates are rare. Antisense
89 RNA transcripts are also hard to detect in patient postmortem tissues. Surprisingly, several
90 studies showed antisense RNA foci are as abundant as sense RNA foci in multiple brain regions
91 [54-56], raising a possibility that antisense C₄G₂ repeat expanded RNAs also contribute to
92 diseases [57]. In this study, we show that antisense C9orf72 C₄G₂ expanded repeats are
93 neurotoxic independent of RAN translated DPR proteins. Antisense C₄G₂, but not sense, repeat
94 expanded RNAs activate PKR/eIF2 α -dependent integrated stress response, leading to global
95 protein synthesis and stress granules formation. Moreover, the phosphorylation of PKR/eIF2 α
96 is significantly increased in C9FTD/ALS patients, suggesting that antisense C₄G₂ repeat
97 expanded RNAs contribute to disease pathogenesis.

98

99 **Results**

100 **C9orf72 antisense C₄G₂ expanded repeats are neurotoxic.**

101 To determine the contribution of C9orf72 antisense repeat expanded RNAs in FTD/ALS
102 pathogenesis, we first generated a construct containing 75 C₄G₂ repeats using recursive
103 directional ligation as previously described [24]. We included 6 stop codons (2 every frame) at
104 the N-terminus to prevent unwarranted translation initiation and 3 protein tags in frame with
105 individual DPR proteins at the C-terminus (**Fig. 1A**). Recent studies have shown that nucleotide
106 sequences at 5'- and 3'- regions of expanded repeats regulate toxicity [58, 59]. Although the
107 molecular mechanism of C9orf72 antisense transcription initiation is unknown, it has been
108 shown that transcription can start from at least 450bp nucleotides upstream [60]. We therefore

109 added 450bp of human sequence at the 5'- region of the antisense C₄G₂ repeats and termed this
110 construct as “in_(C₄G₂)75”. When expressed in HEK293T cells, we detected abundant
111 accumulation of antisense RNA foci, but not in control cells expressing 2 C₄G₂ repeats. Using
112 antibodies against individual DPR proteins RAN translated from C₄G₂ expanded repeat RNAs
113 or the protein tags in frame, we also observed production of GP, PR, and PA DPR proteins
114 only in cells expressing in_(C₄G₂)75 but not 2 repeats (**Fig. S1A-B**). Antisense RNA foci and
115 DPR proteins were also observed in mouse primary cortical neurons expressing in_(C₄G₂)75,
116 but not in neurons expressing 2 repeats (**Figs. 1B and S1C**). Thus, in_(C₄G₂)75 produces
117 antisense RNA foci and DPR proteins, two cellular pathological hallmarks observed in
118 C9FTD/ALS patients.

119 To determine if C9orf72 antisense C₄G₂ expanded repeats can cause neuronal toxicity, we co-
120 transfected in_(C₄G₂)75 or control 2 repeats together with mApple in mouse primary cortical
121 neurons at 4 days in vitro (DIV4) and used automated longitudinal microscopy to track the
122 survival of hundreds of neurons as indicated by the mApple fluorescence over days. Neurons
123 expressing in_(C₄G₂)75 die much faster than those expressing control 2 repeats, suggesting
124 that C9orf72 antisense C₄G₂ expanded repeats are neurotoxic (**Fig. 1C**).

125

126 **C9orf72 antisense C₄G₂ expanded repeats activate PKR/eIF2 α -dependent integrated** 127 **stress response.**

128 We next investigated the molecular mechanism underlying toxicity caused by C9orf72
129 antisense C₄G₂ expanded repeats. More than 50 neurological diseases are genetically associated
130 with microsatellite repeat expansions. Repeat expanded RNAs, including CAG, CUG, CCUG,
131 CAGG, and G₄C₂, have been shown to activate the double-stranded RNA-dependent protein
132 kinase (PKR) [61, 62]. We hypothesized that C9orf72 antisense C₄G₂ expanded RNAs can also
133 activate PKR. HEK293T cells expressing in_(C₄G₂)75 show a significant increase in the level
134 of phosphorylated PKR compared to cells expressing 2 repeats, while the total level of PKR
135 remains unchanged (**Fig. 1D-E**). PKR is one of four kinases that are activated during the
136 integrated stress response (ISR), an evolutionarily conserved stress signaling pathway that
137 adjusts cellular biosynthetic capacity according to need. The four ISR kinases, including PKR,
138 PKR-like ER kinase (PERK), heme-regulated eIF2 α kinase (HRI) and general control non-
139 derepressible 2 (GCN2), respond to distinct environmental and physiological stresses by
140 phosphorylating the eukaryotic translation initiation factor eIF2 α to cause a temporary
141 shutdown of global protein synthesis and upregulation of specific stress-responsive genes [63].
142 Accompanying PKR activation, in_(C₄G₂)75 significantly increases the phosphorylation of

143 eIF2 α without affecting its total level (**Fig. 1F-G**). in_(C4G2)75 activates eIF2 α mainly by the
144 phosphorylation of PKR as other IRS kinases such as PERK phosphorylation are not altered
145 (**Fig. S2A**). Consistent with this, overexpressing wild type (WT) PKR further increases the
146 phosphorylation of eIF2 α induced by in_(C4G2)75, whereas treatment with a specific PKR
147 inhibitor C16 reduces the phosphorylation of both PKR and eIF2 α to a level comparable to that
148 of cells expressing 2 repeats (**Fig 1H-I**). We further expressed in_(C4G2)75 in a neuronal cell
149 line SH-SY5Y that is commonly used to study neurodegeneration and observed similar
150 activation of PKR and eIF2 α by the antisense expanded repeats (**Fig. S2B-C**).

151 To determine whether the activation of PKR/eIF2 α leads to a global mRNA translation
152 inhibition, we employed a puromycin-based, nonradioactive method to monitor protein
153 synthesis [64]. Puromycin is a structure analog of aminoacyl-tRNA that incorporates into
154 nascent polypeptide chains and prevents elongation. The amount of incorporated puromycin
155 detected by antibodies reflects global translation efficacy. HEK293T cells expressing
156 in_(C4G2)75 show a significantly reduced amount of incorporated puromycin compared to
157 those expressing 2 repeats (**Figs. 2A and S2D**). Similarly, neurons expressing 75 antisense
158 repeats, as identified by GP DPR accumulation, have robust global translation inhibition (**Fig.**
159 **2B**). In response to stress-induced translation inhibition, we also observed abundant
160 accumulation of stress granules. Approximately 32% of cells expressing in_(C4G2)75,
161 identified by the presence of antisense RNA foci, show G3BP1-positive stress granules, and
162 ~55% of foci-positive cells stain for FMRP, another commonly used marker for stress granules
163 (**Fig. 2C-D**). These results support that C9orf72 antisense C4G2 expanded repeats activate
164 PKR/eIF2 α -dependent integrated stress response, leading to global translation inhibition and
165 stress granule formation.

166

167 **Antisense C9orf72 repeat expanded RNAs activate the PKR/eIF2 α pathway independent** 168 **of DPR proteins.**

169 We next determined whether the activation of PKR/eIF2 α -dependent integrated stress response
170 is driven by repeat RNA themselves and/or by dipeptide repeat proteins. We first expressed
171 individual codon-optimized, ATG-driven DPR proteins. Neither PR50, PA50 or GP80 activate
172 the phosphorylation of eIF2 α , suggesting that the activation of the PKR/eIF2 α pathway by
173 C9orf72 antisense C4G2 expanded repeats is unlikely due to the DPR proteins produced by
174 RAN translation (**Fig. S3A-B**). To obtain direct evidence that C9orf72 antisense repeat
175 expanded RNAs activate PKR/eIF2 α themselves, we used two strategies to reduce/inhibit DPR
176 proteins without affecting the RNA. First, recent studies have shown that C9orf72 G4C2 sense

177 repeat expanded RNAs initiate RAN translation at a near-cognate CUG codon in the intronic
178 region 24 nucleotides upstream of the repeat sequence [9, 65]. We thus hypothesized that RNA
179 translation from C₄G₂ antisense repeat expanded RNAs might similarly depend on the intronic
180 sequence at the 5' region. We generated a new construct (C₄G₂)₇₅ without including the 450bp
181 human intronic sequence (**Fig. 3A**). Supporting our hypothesis, cells expressing (C₄G₂)₇₅ do
182 not accumulate any detectable GP, PA, or PR DPR proteins, which is strikingly different
183 compared to those expressing in_(C₄G₂)₇₅ with the 450bp human intronic sequence (**Fig. 3B**).
184 The reduced/abolished DPR proteins by (C₄G₂)₇₅ are not due to altered RNA expressions since
185 levels of RNA transcripts and antisense foci are comparable to those of in_(C₄G₂)₇₅ (**Figs. 3C**
186 **and S3C**). Second, we obtained a previously reported stop codon-interrupted 108 antisense
187 repeat construct, designated as RNA only (RO) [(C₄G₂)₁₀₈RO]. It has been shown that this
188 construct is not RAN translated to produce DPR proteins, while still adopts similar stable
189 conformations as the uninterrupted repeat RNAs [51, 52]. As expected, no detectable antisense
190 DPR proteins are observed in cells expressing (C₄G₂)₁₀₈RO, despite abundant accumulation
191 of antisense foci (**Fig. S3C-D**). Interestingly, expression of either (C₄G₂)₇₅ or (C₄G₂)₁₀₈RO
192 leads to the robust activation of PKR and eIF2 α at a comparable level as seen for in_(C₄G₂)₇₅
193 (**Fig. 3D-E**). Thus, C9orf72 antisense repeat expanded RNAs activate the PKR/eIF2 α pathway
194 independent of DPR proteins.

195

196 **Antisense C9orf72 repeat expanded RNAs themselves induce stress granules and lead to** 197 **neuronal toxicity.**

198 Given the conflicting reports of whether C9orf72 antisense RNAs themselves are toxic
199 independent of DPR proteins [11, 51, 52], we next focused on (C₄G₂)₁₀₈RO, which is capable
200 of activating PKR/eIF2 α . We first determined whether this is sufficient to induce stress
201 granules. FMRP is diffused in the cytoplasm of cells expressing 2 C₄G₂ repeats as seen before,
202 but it rapidly assembles into stress granules in cells expressing (C₄G₂)₁₀₈RO. This suggests
203 that antisense C₄G₂ repeat expanded RNAs themselves can trigger stress granule formation in
204 the absence of DPR proteins. (**Fig. 4A-B**). To determine the role of PKR activation in stress
205 granule formation by (C₄G₂)₁₀₈RO, we knocked down PKR using siRNAs. siRNAs targeting
206 PKR reduce its protein level by 80% compared to control siRNAs (**Fig. 4C and S3E**).
207 Consequently, the phosphorylation of eIF2 α by (C₄G₂)₁₀₈RO is almost inhibited (**Fig. 4C and**
208 **S3E**) and the percentage of foci-positive cells with stress granules is significantly reduced (**Fig.**
209 **4D-E**). This data suggests that C9orf72 antisense repeat expanded RNAs themselves induce
210 stress granules by activating PKR/eIF2 α .

211 We further utilized the unbiased longitudinal microscopy assay to determine the risk of death
212 in neurons expressing (C₄G₂)₁₀₈RO. Rodent primary cortical neurons were transfected with
213 mApple and (C₄G₂)₁₀₈RO or 2 repeats and imaged at 24-hour intervals for 10 days. Neurons
214 expressing (C₄G₂)₁₀₈RO show a significant decrease in survival compared to control neurons
215 expressing 2 repeats, suggesting that C9orf72 antisense repeat expanded RNAs themselves are
216 neurotoxic (**Fig. 4F**).

217

218 **Increased levels of phosphorylated PKR and eIF2 α in C9FTD/ALS patients.**

219 To study disease relevance, we determined the levels of phosphorylated PKR and eIF2 α in
220 C9FTD/ALS patient postmortem tissues. Immunohistochemistry staining showed that the level
221 of phosphorylated PKR is increased in the frontal cortex, especially in the large pyramidal
222 neurons, of patients carrying C9orf72 repeat expansions compared to age-matched non-disease
223 controls (**Fig. 5A**). In addition, the level of phosphorylated eIF2 α is also significantly increased
224 after normalizing to the total eIF2 α level, despite the heterogeneity of eIF2 α protein levels in
225 patients (**Fig. 5B**). These results suggest that the PKR/eIF2 α pathway is activated in
226 C9FTD/ALS patients.

227

228 **Sense C9orf72 repeat expanded RNAs cannot activate the PKR/eIF2 α pathway.**

229 By expressing a construct containing (G₄C₂)₁₂₀, Zu *et al.* showed that this repeat expansion
230 construct activates PKR and increases DPR protein translation in HEK293T cells [66].
231 However, it is unknown whether this construct produces antisense (C₄G₂) transcripts that are
232 responsible for the PKR activation. Therefore, we generated a construct with similar repeat
233 length, (G₄C₂)₇₅ (**Fig. S4A**). Consistent with the earlier findings by Zu *et al.*, expression of
234 (G₄C₂)₇₅ in HEK293T cells significantly increases phosphorylation of both PKR and eIF2 α
235 (**Fig. S4B-C**). Interestingly, we detected abundant accumulation of both sense and antisense
236 RNA foci in cells expressing (G₄C₂)₇₅ but not in those expressing 2 repeats (**Fig. S4D**). To
237 determine the relative contribution of sense (G₄C₂) and antisense (C₄G₂) repeat expanded
238 RNAs, we first used previously published antisense oligonucleotides (ASOs) that specifically
239 degrade sense (G₄C₂) RNAs [22]. As expected, ASOs targeting sense RNA repeats
240 significantly reduce the accumulation of sense RNA foci but have little effect on antisense
241 RNA foci (**Figs. 6A-B and S4E**). However, reducing sense RNA transcripts/foci does not alter
242 the activation of PKR/eIF2 α by (G₄C₂)₇₅ (**Figs. 6C-D and S4F-G**). We next designed two
243 ASOs specifically targeting antisense repeat RNAs. Both ASO1 and ASO2 targeting C9orf72
244 antisense RNAs significantly reduce the abundance of antisense RNA foci without affecting

245 sense RNA foci (**Fig. 6E-F**). Consequently, both ASOs significantly inhibit the activation of
246 PKR and eIF2 α by (G₄C₂)₇₅ (**Fig. 6G-H**). Thus, antisense (C₄G₂), but not sense (G₄C₂),
247 C9orf72 repeat expanded RNAs activate the PKR/eIF2 α pathway.

248

249 **Discussion**

250 It is generally accepted in the field that the bidirectionally transcribed repeat expanded RNAs
251 play important roles in FTD/ALS caused by C9orf72 repeat expansions [4]. However, the
252 relative contributions of potential toxic species, including sense and antisense RNAs
253 themselves, RNA foci, and DPR proteins, are largely debated. Our study shows for the first
254 time that C9orf72 antisense (C₄G₂), but not sense (G₄C₂), repeat expanded RNAs activate
255 PKR/eIF2 α -dependent integrated stress response and lead to neurotoxicity independent of DPR
256 proteins in model systems. We also detected increased activation of PKR/eIF2 α in the frontal
257 cortex of C9FTD/ALS patients. Consistent with our observations, increased phosphorylation
258 of PKR has also been reported in BAC transgenic mice expressing 500 G₄C₂ repeats and in
259 C9orf72 patients by two other studies [67, 68].

260

261 Several studies argue against the toxicity from sense (G₄C₂) repeat expanded RNAs and
262 associated RNA foci. In one study, *Drosophila* expressing intronic (G₄C₂)₁₆₀ repeats show
263 abundant sense RNA foci in the nucleus but have little DPR proteins and no neurodegeneration,
264 suggesting that sense RNA foci is insufficient to cause toxicity in this model [52]. Two other
265 elegant studies generated *Drosophila* expressing interrupted (G₄C₂) repeats by inserting stop
266 codons every 12 repeats in all reading frames to prevent RAN translation. These *Drosophila*
267 do not show any toxicity whereas those expressing pure (G₄C₂) repeats of similar sizes do,
268 despite comparable sense RNA foci accumulation. Similarly, *Drosophila* expressing
269 interrupted antisense repeat expanded RNAs do not show any deficits, suggesting that antisense
270 (C₄G₂) RNAs are not toxic in this model system. However, expressing the same antisense
271 interrupted repeat construct (C₄G₂)₁₀₈RO causes motor axonopathy in zebrafish [11].
272 Consistent with this, we show that (C₄G₂)₁₀₈RO is also toxic to primary cortical neurons. It is
273 interesting to note that PKR, which is constitutively and ubiquitously expressed in vertebrate
274 cells including zebrafish, is not found in plants, fungi, protists, or invertebrates such as
275 *Drosophila* [63].

276

277 The contribution of antisense repeat expanded RNAs to C9FTD/ALS pathogenesis is
278 understudied, although PR DPR proteins RAN translated from the antisense RNAs have been

279 shown to be toxic in various model systems [25, 36, 69]. However, aggregates of PR DPR
280 proteins are rare in C9FTD/ALS postmortem tissues, whereas antisense RNA foci are as
281 abundant as sense RNA foci in multiple CNS regions despite scarcity of antisense RNA
282 transcripts. One possibility of such discrepancy between RNA transcript and foci levels is that
283 antisense RNA foci are extraordinarily stable and rarely turn over once formed along the
284 lifespan of patients. Several neuropathological studies have attempted to correlate the
285 abundance and distribution of antisense RNA foci with C9FTD/ALS clinical features.
286 Mizielinska *et al.* showed that patients with more antisense RNA foci tend to have an earlier
287 age of symptom onset [54] and more intriguingly, antisense RNA foci are shown to be
288 associated with nucleoli and mislocalization of TDP-43 in two different studies [70, 71]. These
289 results highlight the disease relevance of antisense repeat expanded RNAs in C9FTD/ALS and
290 the significance of our work. Our study, however, does not differentiate antisense RNA foci
291 from RNAs themselves since it is technically challenging given that RNA foci inevitably form
292 with the expression of repeat expanded RNAs. The proposed mechanisms of RNA foci-
293 mediated toxicity are via sequestration of critical RBPs. Several RBPs have been proposed to
294 interact with and/or are sequestered into sense RNA foci, yet those interacting with antisense
295 RNA foci have not been well characterized and are worth exploring especially in correlation
296 with PKR/eIF2 α activation.

297
298 How is PKR specifically activated by C9orf72 antisense, but not sense repeat expanded RNAs?
299 PKR is a stress sensor first identified as a kinase responding to viral infections by directly
300 binding to viral double stranded RNAs (dsRNAs) [63]. Several disease relevant repeats
301 expanded RNAs, such as CUG and CGG, have been shown to form stable hairpins and directly
302 bind to PKR, leading to its activation [61, 62]. It is possible that antisense (C₄G₂) RNAs form
303 similar hairpin structures, which has not been well studied. Supporting this, antisense (C₄G₂)
304 DNAs form i-motifs consisting of two parallel duplexes in a head to tail orientation as well as
305 protonated hairpins under near-physiological conditions [72]. In contrast, sense (G₄C₂) RNAs
306 tend to form stable unimolecular and multimolecular G-quadruplexes [73, 74]. In addition to
307 C9orf72 antisense repeat expanded RNAs, short and long interspersed retrotransposable
308 elements (SINEs and LINEs) and endogenous retroviruses (ERVs) represent other main
309 sources of endogenous dsRNAs [75]. In C9orf72 patients, transcripts from multiple classes of
310 repetitive elements are significantly elevated [76]. Other PKR activators include cellular
311 stresses such as oxidative stress, intracellular calcium increase or ER stress, as well as
312 interferon-gamma (IFN γ), tumor necrosis factor α (TNF α), heparin, and platelet-derived

313 growth factor [63]. Whether C9orf72 antisense (C₄G₂) expanded RNAs specifically increase
314 transcription of RNAs with repetitive elements or other PKR activators warrants additional
315 studies.

316 Our study shows that C9orf72 antisense (C₄G₂) expanded repeats promotes robust global
317 translation inhibition and stress granule formation independent of DPR proteins via the
318 activation of the PKR/eIF2 α pathway. Stress granules are dynamic structures that form and
319 disperse rapidly with acute stress. However, chronic stress during aging or under pathological
320 conditions leads to altered stress granule dynamics and persistent stress granules, which have
321 been implicated to the aggregation of RBPs such as TDP-43 and contribute to the pathogenesis
322 of FTD and ALS. For C9orf72 FTD/ALS, several studies show that DPR proteins such as GR,
323 PR and GA are toxic [23-25, 36-50]. It has been shown that GR and PR can also inhibit global
324 protein translation via direct binding to mRNAs to block access to the translational machinery
325 [40]. Interestingly, the RAN translation of DPR proteins is specifically increased by the
326 integrated stress response via eIF2 α phosphorylation [65, 77]. Thus, activation of PKR/eIF2 α
327 by C9orf72 antisense repeat expanded RNAs will lead to additional accumulation of DPR
328 proteins and toxicity.

329
330 From the therapeutic development point of view, several approaches have been explored to
331 mitigate gain of toxicity from C9orf72 repeat expanded RNAs [4]. Our previous work with
332 ASOs targeting C9orf72 sense (G₄C₂) repeat expanded RNAs showed great promise in a
333 preclinical mouse model expressing 450 (G₄C₂) repeats [22]. Unfortunately, there was a recent
334 setback in the clinical trial using these ASOs to treat C9ALS patients. Although many different
335 confounding reasons may cause drug failure, further understanding of disease mechanisms is
336 required to develop successful therapies for C9FTD/ALS. On this note, Zu *et al.* recently
337 showed that metformin, an FDA approved drug widely used for treating type 2 diabetes,
338 inhibits PKR activation, reduces DPR proteins RAN translated from the sense strand, and
339 improves behavioral and pathological deficits in BAC transgenic mice expressing G₄C₂ repeats
340 [68]. Our study highly suggests that the activation of PKR in these BAC transgenic mice and
341 in C9orf72 patients might result from the antisense repeat expanded RNAs. Future therapies
342 targeting C9orf72 antisense RNAs and/or altered downstream molecular pathways hold great
343 promise for these devastating neurodegenerative diseases.

344

345 **Materials and Methods**

346

347 **Plasmids and siRNAs**

348
349 A construct containing 10 GGGGCC repeats, flanked 5' by BbsI and 3' by BsmBI recognition
350 sites, was synthesized by GENEWIZ and used to generate antisense (C₄G₂) repeats using
351 recursive directional ligation as previously described [24]. The repeat-containing plasmids
352 were amplified using recombination deficient Stbl3 *E. coli* (Life Technologies) at 32°C to
353 minimize retraction of repeats. Human PKR cDNA was a gift from Dr. Thomas Dever (NIH,
354 USA) and (C₄G₂)₁₀₈RO was gifted by Dr. Adrian Isaac [51]. For longitudinal fluorescence
355 microscopy pGW1-mApple was used. All plasmids were verified by Sanger sequencing
356 (Genewiz, USA). All ASOs were synthesized by Integrated DNA Technologies, USA. siRNAs
357 against PKR and control siRNAs were purchased from Horizon Discovery, USA.

358

359 **Human tissues**

360 Post-mortem brain tissues from C9FTD/ALS patients (n=6) and controls (n=6) were obtained
361 from the Emory Neuropathology Core. Patient information is provided in Table S1.

362

363 **Cell culture and transfection**

364

365 Human embryonic kidney (HEK293T) and human neuroblastoma (SH-SY5Y) cells from
366 ATCC were cultured in high glucose DMEM (Invitrogen) and DMEM-F12 (Invitrogen),
367 respectively (supplemented with 10% fetal bovine serum (Corning), 4 mM Glutamax
368 (Invitrogen), penicillin (100 U/mL), streptomycin (100 µg/mL) and non-essential amino acids
369 (1%). Cells were grown at 37°C in a humidified atmosphere with 5% CO₂. Cells were
370 transiently transfected using polyethyleneimine or lipofectamine. Experiments were performed
371 48 hours after transfection.

372

373 **Primary cortical neuronal culture and transfection**

374

375 Primary cortical neurons were prepared from C57BL/6J mouse embryos (Charles River) of
376 either sex on embryonic day 17. Cerebral cortices were dissected and enzymatically dissociated
377 using trypsin with EDTA (Thermo Fisher Scientific; 10 minutes), mechanically dissociated in
378 Minimum Essential Media (MEM; Fisher) supplemented with 0.6% glucose (Sigma) and 10%
379 Fetal Bovine Serum (FBS; Hyclone) and stained to assess viability using Trypan Blue (Sigma).
380 Neurons were plated on coverslips (Matsunami Inc., 22 mm) or MatTek dishes coated with
381 poly-L-lysine (Sigma). A total of 50,000 neurons were plated as a 'spot' on the center of the
382 coverslip to create a small, high-density network. Neurons were cultured in standard growth

383 medium [glial conditioned neurobasal plus medium (Fisher) supplemented with Glutamax
384 (GIBCO) and B27 plus (Invitrogen)], and half of the media was exchanged 2-3 times a week
385 until the experiment endpoints. No antibiotics or antimycotics were used. Cultures were
386 maintained in an incubator regulated at 37 °C, 5% CO₂ and 95% relative humidity as described
387 [78]. Cells were transiently transfected using Lipofectamine 2000 (Invitrogen) according to the
388 manufacturer's instructions.

389

390 **Longitudinal fluorescence microscopy**

391

392 Mouse primary cortical neurons were transfected with mApple and repeat expanded constructs
393 and imaged by fluorescence microscopy at 24-hour intervals for 7-10 days as described [79].
394 Time of death was determined based on rounding of the soma, retraction of neurites, or loss of
395 fluorescence. The time of death for individual neurons was used to calculate the risk of death
396 in each population relative to a reference group. Images were acquired using Keyence BZ-
397 X810 microscope with a 10× objective and analyzed by Image J. The images were stitched and
398 stacked, and cell death was scored using the criteria mentioned above.

399

400 **RNA fluorescence in situ hybridization**

401

402 LNA DNA probes were used against the sense and antisense hexanucleotide repeat expanded
403 RNAs (Exiqon, Inc.). The probe sequence for detecting sense RNA foci: TYE563-
404 CCCC GGCCCC GGCCCC; and that for antisense RNA foci is: TYE563-
405 GGGGCCGGGGCCGGGG. All hybridization steps were performed under RNase-free
406 conditions. Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 20
407 minutes, washed three times for 5 minutes with phosphate buffer saline (DEPC 1× PBS,
408 Corning) followed by permeabilization with 0.2% Triton-X 100 (Sigma) for 10 minutes and
409 then incubated with 2× SSC buffer for 10 minutes. Cells were hybridized (50% formamide, 2×
410 SCC, 50 mM sodium phosphate (pH 7), 10% dextran sulfate, and 2 mM vanadyl sulfate
411 ribonucleosides) with denatured probes (final concentration of 40 nM) at 66°C for 2 hours.
412 After hybridization, slides were washed at room temperature in 0.1% Tween-20/2×SCC for 10
413 minutes twice and in stringency washes in 0.1× SCC at 65°C for 10 minutes. Cell nuclei were
414 stained with DAPI. Three to six random pictures were taken by Keyence BZ-X810 microscope
415 with a 60× oil objective and analyzed by Image J.

416

417 **Immunofluorescence**

418
419 Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 20 minutes,
420 washed three times for 5 minutes with phosphate buffer saline (1× PBS, Corning) and treated
421 with 0.2% Triton-X 100 (Sigma) in PBS for 10 minutes. Cells were blocked for 30 minutes in
422 a blocking solution consisting of 4% bovine serum albumin (Sigma) in PBS. Cells were
423 incubated overnight in primary antibodies diluted in blocking solution. The next day, cells were
424 washed 3 times for 5 minutes in PBS and incubated in secondary antibodies in blocking
425 solution for one hour at room temperature (dark). After washing 3 times for 5 minutes,
426 coverslips with the cells were mounted using Prolong Gold Antifade mounting media
427 (Invitrogen). Images were acquired with Keyence BZ-X810 microscope with a 60× oil
428 objective and analyzed by Image J.

429

430 **Immunohistochemistry**

431
432 Post-mortem brain tissues were obtained from the brain bank maintained by the Emory
433 Alzheimer Disease Research Center under proper Institutional Review Board protocols.
434 Paraffin-embedded sections from frontal cortex (8 μm thickness) were deparaffinized by
435 incubation at 60°C for 30 minutes and rehydrated by immersion in graded ethanol solutions.
436 Antigen retrieval was done by microwaving in a 10 mM citrate buffer (pH 6.0) for 5 minutes
437 followed by allowing slides to cool to room temperature for 30 minutes. Endogenous
438 peroxidase activity was eliminated by incubating slides with hydrogen peroxide block solution
439 (Fisher) for 10 minutes at room temperature followed by rinsing in phosphate buffered saline.
440 Non-specific binding was reduced by blocking in ultra-Vision Block (Fisher) for 5 minutes at
441 room temperature. Sections were then incubated overnight with primary antibodies diluted in
442 1% BSA in phosphate buffered saline for 30 minutes at room temperature or incubated without
443 primary antibody as a negative control. Sections were rinsed in phosphate buffered saline and
444 incubated in labeled ultra Vision LP detection system horseradish peroxidase-polymer
445 secondary antibody (Fisher) for 15 minutes at room temperature. Slides were imaged for
446 analysis using an Aperio Digital Pathology Slide Scanner (Leica Biosystems). For IHC, rabbit
447 anti-p-PKR, Millipore 07-532 (1:100 dilution) antibody was used.

448

449 **Protein lysate preparation**

450

451 Whole cell/tissue extracts were lysed using RIPA Lysis Buffer pH 7.4 (Bio-world, USA)
452 supplemented with Halt™ protease and phosphatase inhibitor cocktail (ThermoFisher

453 Scientific). Lysates were sonicated at 25% amplitude for 3 cycles for 15 seconds with 5 second
454 intervals. Supernatant was collected after centrifuging at max speed for 15 minutes at 4°C. The
455 concentration of the isolated proteins was determined using BCA Protein Assay Reagent
456 (Pierce, USA).

457

458

459 **Immunoblotting assay**

460

461 For western blotting, 20-30 µg of proteins were prepared in 4× laemmli sample buffer and heat-
462 denatured at 95°C for 5 minutes. Samples were resolved on 4–20% gradient gels (Bio-Rad).
463 Proteins were transferred to nitrocellulose membranes (0.2 µm, Bio-Rad). The membrane was
464 blocked in 5 % milk and incubated overnight at 4°C with primary antibodies diluted in blocking
465 buffer. Secondary antibodies HRP-conjugated secondary antibodies (Abclonal) or IRDye
466 secondary antibodies (Li-cor) were diluted in blocking buffer and applied to the membrane for
467 1 hour at room temperature. Primary antibodies used: mouse anti-FLAG (1:1000; Sigma),
468 rabbit anti-HA (1:1000; CST), mouse anti-MYC (1:1000; Sigma), rabbit anti-PKR (1:1000;
469 abcam), rabbit anti-phospho-PKR (1:1000; abcam), rabbit anti-eIF2α (1:1000; CST), rabbit
470 anti-phospho-eIF2α (1:1000; CST), rabbit anti-PERK (1:1000; CST), rabbit anti-phospho-
471 PERK (1:1000; abcam), rabbit anti-GAPDH (1:5000; CST). Antibodies against PR, GP and
472 PA have been previously reported [22]. Super Signal West Pico (Pierce, USA) was used for
473 detection of peroxidase activity. Molecular masses were determined by comparison to protein
474 standards (Thermo Scientific). The immunoreactive bands were detected by ChemiDoc Image
475 System (Bio-Rad, USA).

476

477 **Quantitative real-time PCR**

478

479 Total RNAs were extracted using a RNeasy kit as instructed by the manufacturer (Qiagen).
480 cDNA was prepared using High-Capacity cDNA Reverse Transcription Kit from applied
481 biosystem. Quantitative RT-PCR reactions were conducted and analyzed on a StepOnePlus
482 Real-Time PCR system (Applied Biosystems). Gene expression levels were measured by
483 SYBR green (Thermo Fisher Scientific) quantitative real-time PCR.

484

485 **Statistical analysis**

486 Statistical analyses and graphs were prepared in GraphPad Prism (version 9). Data is expressed
487 as mean \pm S.D. as shown in figure legends. Student t-test or one-way ANOVA was used for
488 statistical analysis unless specified in figure legends.

489

490 References

491

- 492 1. Renton, A.E., et al., *A hexanucleotide repeat expansion in C9ORF72 is the cause of*
493 *chromosome 9p21-linked ALS-FTD*. *Neuron*, 2011. **72**(2): p. 257-68.
- 494 2. DeJesus-Hernandez, M., et al., *Expanded GGGGCC hexanucleotide repeat in*
495 *noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS*. *Neuron*,
496 2011. **72**(2): p. 245-56.
- 497 3. La Spada, A.R. and J.P. Taylor, *Repeat expansion disease: progress and puzzles in*
498 *disease pathogenesis*. *Nat Rev Genet*, 2010. **11**(4): p. 247-58.
- 499 4. Jiang, J. and J. Ravits, *Pathogenic Mechanisms and Therapy Development for C9orf72*
500 *Amyotrophic Lateral Sclerosis/Frontotemporal Dementia*. *Neurotherapeutics*, 2019.
501 **16**(4): p. 1115-1132.
- 502 5. van Blitterswijk, M., et al., *Novel clinical associations with specific C9ORF72*
503 *transcripts in patients with repeat expansions in C9ORF72*. *Acta Neuropathol*, 2015.
504 **130**(6): p. 863-76.
- 505 6. Gijssels, I., et al., *A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort*
506 *with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis*
507 *spectrum: a gene identification study*. *Lancet Neurol*, 2012. **11**(1): p. 54-65.
- 508 7. Ash, P.E., et al., *Unconventional translation of C9ORF72 GGGGCC expansion*
509 *generates insoluble polypeptides specific to c9FTD/ALS*. *Neuron*, 2013. **77**(4): p. 639-
510 46.
- 511 8. McEachin, Z.T., et al., *Chimeric Peptide Species Contribute to Divergent Dipeptide*
512 *Repeat Pathology in c9ALS/FTD and SCA36*. *Neuron*, 2020. **107**(2): p. 292-305.e6.
- 513 9. Tabet, R., et al., *CUG initiation and frameshifting enable production of dipeptide repeat*
514 *proteins from ALS/FTD C9ORF72 transcripts*. *Nat Commun*, 2018. **9**(1): p. 152.
- 515 10. Gao, F.B., J.D. Richter, and D.W. Cleveland, *Rethinking Unconventional Translation*
516 *in Neurodegeneration*. *Cell*, 2017. **171**(5): p. 994-1000.
- 517 11. Swinnen, B., et al., *A zebrafish model for C9orf72 ALS reveals RNA toxicity as a*
518 *pathogenic mechanism*. *Acta Neuropathol*, 2018. **135**(3): p. 427-443.
- 519 12. Therrien, M., et al., *Deletion of C9ORF72 results in motor neuron degeneration and*
520 *stress sensitivity in C. elegans*. *PLoS One*, 2013. **8**(12): p. e83450.
- 521 13. Koppers, M., et al., *C9orf72 ablation in mice does not cause motor neuron*
522 *degeneration or motor deficits*. *Ann Neurol*, 2015. **78**(3): p. 426-38.
- 523 14. Atanasio, A., et al., *C9orf72 ablation causes immune dysregulation characterized by*
524 *leukocyte expansion, autoantibody production, and glomerulonephropathy in mice*. *Sci*
525 *Rep*, 2016. **6**: p. 23204.
- 526 15. Sudria-Lopez, E., et al., *Full ablation of C9orf72 in mice causes immune system-related*
527 *pathology and neoplastic events but no motor neuron defects*. *Acta Neuropathol*, 2016.
528 **132**(1): p. 145-7.
- 529 16. O'Rourke, J.G., et al., *C9orf72 is required for proper macrophage and microglial*
530 *function in mice*. *Science*, 2016. **351**(6279): p. 1324-9.

- 531 17. Sullivan, P.M., et al., *The ALS/FTLD associated protein C9orf72 associates with*
532 *SMCR8 and WDR41 to regulate the autophagy-lysosome pathway.* Acta Neuropathol
533 Commun, 2016. **4**(1): p. 51.
- 534 18. Ugolino, J., et al., *Loss of C9orf72 Enhances Autophagic Activity via Deregulated*
535 *mTOR and TFEB Signaling.* PLoS Genet, 2016. **12**(11): p. e1006443.
- 536 19. Burberry, A., et al., *Loss-of-function mutations in the C9ORF72 mouse ortholog cause*
537 *fatal autoimmune disease.* Sci Transl Med, 2016. **8**(347): p. 347ra93.
- 538 20. Harms, M.B., et al., *Lack of C9ORF72 coding mutations supports a gain of function*
539 *for repeat expansions in amyotrophic lateral sclerosis.* Neurobiol Aging, 2013. **34**(9):
540 p. 2234 e13-9.
- 541 21. Chew, J., et al., *Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-*
542 *43 pathology, neuronal loss, and behavioral deficits.* Science, 2015. **348**(6239): p.
543 1151-4.
- 544 22. Jiang, J., et al., *Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72*
545 *Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.*
546 Neuron, 2016. **90**(3): p. 535-50.
- 547 23. Choi, S.Y., et al., *C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and*
548 *compromises mitochondrial function in vivo.* Nat Neurosci, 2019. **22**(6): p. 851-862.
- 549 24. Mizielinska, S., et al., *C9orf72 repeat expansions cause neurodegeneration in*
550 *Drosophila through arginine-rich proteins.* Science, 2014. **345**(6201): p. 1192-1194.
- 551 25. Zhang, Y.J., et al., *Heterochromatin anomalies and double-stranded RNA*
552 *accumulation underlie C9orf72 poly(PR) toxicity.* Science, 2019. **363**(6428).
- 553 26. Zhu, Q., et al., *Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-*
554 *causing repeat expansion in C9orf72.* Nat Neurosci, 2020. **23**(5): p. 615-624.
- 555 27. Boivin, M., et al., *Reduced autophagy upon C9ORF72 loss synergizes with dipeptide*
556 *repeat protein toxicity in G4C2 repeat expansion disorders.* EMBO J, 2020. **39**(4): p.
557 e100574.
- 558 28. Donnelly, C.J., et al., *RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated*
559 *by antisense intervention.* Neuron, 2013. **80**(2): p. 415-28.
- 560 29. Sareen, D., et al., *Targeting RNA foci in iPSC-derived motor neurons from ALS patients*
561 *with a C9ORF72 repeat expansion.* Sci Transl Med, 2013. **5**(208): p. 208ra149.
- 562 30. Lee, Y.B., et al., *Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci,*
563 *sequester RNA binding proteins, and are neurotoxic.* Cell Rep, 2013. **5**(5): p. 1178-86.
- 564 31. Mori, K., et al., *hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-*
565 *positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72*
566 *mutations.* Acta Neuropathol, 2013. **125**(3): p. 413-23.
- 567 32. Xu, Z., et al., *Expanded GGGGCC repeat RNA associated with amyotrophic lateral*
568 *sclerosis and frontotemporal dementia causes neurodegeneration.* Proc Natl Acad Sci
569 U S A, 2013. **110**(19): p. 7778-83.
- 570 33. Haeusler, A.R., et al., *C9orf72 nucleotide repeat structures initiate molecular cascades*
571 *of disease.* Nature, 2014. **507**(7491): p. 195-200.
- 572 34. Conlon, E.G., et al., *The C9ORF72 GGGGCC expansion forms RNA G-quadruplex*
573 *inclusions and sequesters hnRNP H to disrupt splicing in ALS brains.* Elife, 2016. **5**.
- 574 35. Celona, B., et al., *Suppression of C9orf72 RNA repeat-induced neurotoxicity by the*
575 *ALS-associated RNA-binding protein Zfp106.* Elife, 2017. **6**.
- 576 36. Wen, X., et al., *Antisense proline-arginine RAN dipeptides linked to C9ORF72-*
577 *ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal*
578 *death.* Neuron, 2014. **84**(6): p. 1213-25.

- 579 37. Tao, Z., et al., *Nucleolar stress and impaired stress granule formation contribute to*
580 *C9orf72 RAN translation-induced cytotoxicity*. Hum Mol Genet, 2015. **24**(9): p. 2426-
581 41.
- 582 38. Lee, K.H., et al., *C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and*
583 *Function of Membrane-Less Organelles*. Cell, 2016. **167**(3): p. 774-788 e17.
- 584 39. Zu, T., et al., *Non-ATG-initiated translation directed by microsatellite expansions*. Proc
585 Natl Acad Sci U S A, 2011. **108**(1): p. 260-5.
- 586 40. Kanekura, K., et al., *Poly-dipeptides encoded by the C9ORF72 repeats block global*
587 *protein translation*. Hum Mol Genet, 2016. **25**(9): p. 1803-13.
- 588 41. Zhang, Y.J., et al., *Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins*
589 *cause neurotoxicity by inducing ER stress*. Acta Neuropathol, 2014. **128**(4): p. 505-24.
- 590 42. May, S., et al., *C9orf72 FTL/ALS-associated Gly-Ala dipeptide repeat proteins cause*
591 *neuronal toxicity and Unc119 sequestration*. Acta Neuropathol, 2014. **128**(4): p. 485-
592 503.
- 593 43. Yamakawa, M., et al., *Characterization of the dipeptide repeat protein in the molecular*
594 *pathogenesis of c9FTD/ALS*. Hum Mol Genet, 2015. **24**(6): p. 1630-45.
- 595 44. Freibaum, B.D., et al., *GGGGCC repeat expansion in C9orf72 compromises*
596 *nucleocytoplasmic transport*. Nature, 2015. **525**(7567): p. 129-33.
- 597 45. Yang, D., et al., *FTD/ALS-associated poly(GR) protein impairs the Notch pathway and*
598 *is recruited by poly(GA) into cytoplasmic inclusions*. Acta Neuropathol, 2015. **130**(4):
599 p. 525-35.
- 600 46. Boeynaems, S., et al., *Drosophila screen connects nuclear transport genes to DPR*
601 *pathology in c9ALS/FTD*. Sci Rep, 2016. **6**: p. 20877.
- 602 47. Zhang, Y.J., et al., *C9ORF72 poly(GA) aggregates sequester and impair HR23 and*
603 *nucleocytoplasmic transport proteins*. Nat Neurosci, 2016. **19**(5): p. 668-677.
- 604 48. Schludi, M.H., et al., *Spinal poly-GA inclusions in a C9orf72 mouse model trigger*
605 *motor deficits and inflammation without neuron loss*. Acta Neuropathol, 2017. **134**(2):
606 p. 241-254.
- 607 49. Zhang, Y.J., et al., *Poly(GR) impairs protein translation and stress granule dynamics*
608 *in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis*. Nat
609 Med, 2018. **24**(8): p. 1136-1142.
- 610 50. Hao, Z., et al., *Motor dysfunction and neurodegeneration in a C9orf72 mouse line*
611 *expressing poly-PR*. Nat Commun, 2019. **10**(1): p. 2906.
- 612 51. Moens, T.G., et al., *Sense and antisense RNA are not toxic in Drosophila models of*
613 *C9orf72-associated ALS/FTD*. Acta Neuropathol, 2018. **135**(3): p. 445-457.
- 614 52. Tran, H., et al., *Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat*
615 *Proteins in a Drosophila Model of C9ORF72 FTD/ALS*. Neuron, 2015. **87**(6): p. 1207-
616 1214.
- 617 53. Zhang, K., et al., *The C9orf72 repeat expansion disrupts nucleocytoplasmic transport*.
618 Nature, 2015. **525**(7567): p. 56-61.
- 619 54. Mizielinska, S., et al., *C9orf72 frontotemporal lobar degeneration is characterised by*
620 *frequent neuronal sense and antisense RNA foci*. Acta Neuropathol, 2013. **126**(6): p.
621 845-57.
- 622 55. DeJesus-Hernandez, M., et al., *In-depth clinico-pathological examination of RNA foci*
623 *in a large cohort of C9ORF72 expansion carriers*. Acta Neuropathol, 2017. **134**(2): p.
624 255-269.
- 625 56. Vatsavayai, S.C., et al., *C9orf72-FTD/ALS pathogenesis: evidence from human*
626 *neuropathological studies*. Acta Neuropathol, 2019. **137**(1): p. 1-26.
- 627 57. McEachin, Z.T., et al., *RNA-mediated toxicity in C9orf72 ALS and FTD*. Neurobiol Dis,
628 2020. **145**: p. 105055.

- 629 58. Sellier, C., et al., *Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic*
630 *and May Contribute to Fragile X Tremor Ataxia Syndrome*. *Neuron*, 2017. **93**(2): p.
631 331-347.
- 632 59. He, F., et al., *The carboxyl termini of RAN translated GGGGCC nucleotide repeat*
633 *expansions modulate toxicity in models of ALS/FTD*. *Acta Neuropathol Commun*, 2020.
634 **8**(1): p. 122.
- 635 60. Zu, T., et al., *RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS*
636 *and frontotemporal dementia*. *Proc Natl Acad Sci U S A*, 2013. **110**(51): p. E4968-77.
- 637 61. Handa, V., T. Saha, and K. Usdin, *The fragile X syndrome repeats form RNA hairpins*
638 *that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer*.
639 *Nucleic Acids Res*, 2003. **31**(21): p. 6243-8.
- 640 62. Tian, B., et al., *Expanded CUG repeat RNAs form hairpins that activate the double-*
641 *stranded RNA-dependent protein kinase PKR*. *Rna*, 2000. **6**(1): p. 79-87.
- 642 63. Martinez, N.W., F.E. Gomez, and S. Matus, *The Potential Role of Protein Kinase R as*
643 *a Regulator of Age-Related Neurodegeneration*. *Front Aging Neurosci*, 2021. **13**: p.
644 638208.
- 645 64. Schmidt, E.K., et al., *SUnSET, a nonradioactive method to monitor protein synthesis*.
646 *Nat Methods*, 2009. **6**(4): p. 275-7.
- 647 65. Green, K.M., et al., *RAN translation at C9orf72-associated repeat expansions is*
648 *selectively enhanced by the integrated stress response*. *Nat Commun*, 2017. **8**(1): p.
649 2005.
- 650 66. Zu, T., et al., *Metformin inhibits RAN translation through PKR pathway and mitigates*
651 *disease in C9orf72 ALS/FTD mice*. *Proceedings of the National Academy*
652 *of Sciences*, 2020: p. 202005748.
- 653 67. Rodriguez, S., et al., *Genome-encoded cytoplasmic double-stranded RNAs, found in*
654 *C9ORF72 ALS-FTD brain, propagate neuronal loss*. *Sci Transl Med*, 2021. **13**(601).
- 655 68. Zu, T., et al., *Metformin inhibits RAN translation through PKR pathway and mitigates*
656 *disease in C9orf72 ALS/FTD mice*. *Proc Natl Acad Sci U S A*, 2020. **117**(31): p. 18591-
657 18599.
- 658 69. Jovicic, A., et al., *Modifiers of C9orf72 dipeptide repeat toxicity connect*
659 *nucleocytoplasmic transport defects to FTD/ALS*. *Nat Neurosci*, 2015. **18**(9): p. 1226-
660 9.
- 661 70. Aladesuyi Arogundade, O., et al., *Antisense RNA foci are associated with nucleoli and*
662 *TDP-43 mislocalization in C9orf72-ALS/FTD: a quantitative study*. *Acta Neuropathol*,
663 2019. **137**(3): p. 527-530.
- 664 71. Cooper-Knock, J., et al., *Antisense RNA foci in the motor neurons of C9ORF72-ALS*
665 *patients are associated with TDP-43 proteinopathy*. *Acta Neuropathol*, 2015. **130**(1):
666 p. 63-75.
- 667 72. Kovanda, A., et al., *Anti-sense DNA d(GGCCCC)_n expansions in C9ORF72 form i-*
668 *motifs and protonated hairpins*. *Sci Rep*, 2015. **5**: p. 17944.
- 669 73. Reddy, K., et al., *The disease-associated r(GGGGCC)_n repeat from the C9orf72 gene*
670 *forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures*. *J*
671 *Biol Chem*, 2013. **288**(14): p. 9860-6.
- 672 74. Fratta, P., et al., *C9orf72 hexanucleotide repeat associated with amyotrophic lateral*
673 *sclerosis and frontotemporal dementia forms RNA G-quadruplexes*. *Sci Rep*, 2012. **2**:
674 p. 1016.
- 675 75. Sadeq, S., et al., *Endogenous Double-Stranded RNA*. *Noncoding RNA*, 2021. **7**(1).
- 676 76. Prudencio, M., et al., *Repetitive element transcripts are elevated in the brain of C9orf72*
677 *ALS/FTLD patients*. *Hum Mol Genet*, 2017. **26**(17): p. 3421-3431.

- 678 77. Cheng, W., et al., *C9ORF72 GGGGCC repeat-associated non-AUG translation is*
679 *upregulated by stress through eIF2alpha phosphorylation*. Nat Commun, 2018. **9**(1):
680 p. 51.
- 681 78. Valdez-Sinon, A.N., et al., *Cdh1-APC Regulates Protein Synthesis and Stress Granules*
682 *in Neurons through an FMRP-Dependent Mechanism*. iScience, 2020. **23**(5): p.
683 101132.
- 684 79. Weskamp, K., et al., *Monitoring Neuronal Survival via Longitudinal Fluorescence*
685 *Microscopy*. J Vis Exp, 2019(143).

686

687 **Acknowledgements:** We thank current and past members of Jiang, Bassell labs and Dr. Homa
688 Ghalei for many helpful discussions. We would like to thank Dr. Jonathan Glass for providing
689 access to the patient samples (Emory cohort). We would like to thank Dr. Yao Yao and Dr.
690 Zachary McEachin for providing sense and control ASOs, respectively.

691

692 **Funding:** JP is supported by the Milton Safenowitz Postdoctoral Fellowship from the ALS
693 association (Grant# 21-PDF-585 to JP).

694 AB and GJB are supported by the NIH R01 (R01NS114253 to GJB).

695 The work is supported by the NIH R01 grant R01AG068247 to JJ.

696

697 **Author contributions:** JP performed and analyzed all *in vitro* experiments. SA performed IHC
698 in patient tissues. CZ, KT, DCP and GC helped in cell-based experiments and analysis. JP and
699 JJ wrote the manuscript.

700

701 **Competing interests:** All authors declare they have no competing interests.

702

703 **Data and materials availability:** All data are available in the main text or the supplementary
704 materials.

705

706

707 **Figures Legends**

708

709

710 **Figure 1. C9orf72 C4G₂ expanded repeats activate PKR/eIF2 α -dependent integrated**
711 **stress response and cause neuronal toxicity.**

712 (A) Schematic illustration of the in_(C4G₂)₇₅ repeat construct including 6 \times stop codons,
713 450bp of human intronic sequences at the N-terminus and 3 \times protein tags at the C- terminus of
714 the repeats to monitor the DPR proteins in each frame. (B) Representative images of antisense
715 RNA foci in HEK293T cells and in primary cortical neurons expressing in_(C4G₂)₇₅ repeats
716 detected by RNA FISH. Red, foci; blue, DAPI; magenta, MAP2. (C) Kaplan-Meier curves
717 showing increased risk of cell death in in_(C4G₂)₇₅ expressing primary cortical neurons

718 compared with 2 repeats. Statistical analyses were performed using Mantel-Cox test. **(D-E)**
719 Immunoblotting analysis of phosphorylated PKR (p-PKR) and total PKR in HEK293T cells
720 expressing in_{(C₄G₂)75} or 2 repeats. p-PKR levels were detected using anti-p-PKR (T446) and
721 normalized to total PKR. GAPDH was used as a loading control. Error bars represent S.D. (n=3
722 independent experiments). Statistical analyses were performed using student's t-test. **(F-G)**
723 Immunoblotting analysis of Phosphorylated eIF2 α (p-eIF2 α) and total eIF2 α in HEK293T cells
724 expressing in_{(C₄G₂)75} or 2 repeats. p-eIF2 α levels were detected using anti-phosphor eIF2 α
725 (Ser51) and normalized to total eIF2 α . GAPDH was used as a loading control. Error bars
726 represent S.D. (n=3 independent experiments). Statistical analyses were performed using
727 student's t-test. **(H)** Immunoblotting analysis of p-PKR and p-eIF2 α in HEK293T cells
728 expressing in_{(C₄G₂)75}, with or without co-expression of wild type PKR, or treatment of a
729 PKR inhibitor, C16. Error bars represent S.D. (n=2 independent experiments). Statistical
730 analyses were performed using one-way ANOVA with Tukey's post hoc test.

731

732 **Figure 2. C9orf72 C₄G₂ expanded repeats inhibit global protein synthesis and induce**
733 **stress granule assembly.**

734 **(A)** Immunoblotting of puromycin in HEK293T cells expressing in_{(C₄G₂)75} or 2 repeats.
735 Cells were incubated with puromycin for 30 minutes before harvesting. **(B)** Representative
736 images of primary neurons expressing either (C₄G₂)75 or 2 repeats stained with anti-puromycin
737 (red), anti-FLAG (green), DAPI (blue) and MAP2 (magenta). Quantification of puromycin
738 intensity in neurons expressing in_{(C₄G₂)75} or 2 repeats. Error bars represent S.D. (n=40-50
739 neurons/group. Similar results were obtained from two independent experiments). Statistical
740 analyses were performed using student's t-test. **(C)** Representative images of G3BP1 and
741 FMRP staining in HEK293T cells expressing in_{(C₄G₂)75} repeats identified by the presence
742 of RNA foci using FISH. **(D)** Quantification of antisense foci positive cells with G3BP1 and
743 FMRP granules. Error bars represent S.D. (n=150 cells/condition and three independent
744 experiments). Statistical analyses were performed using student's t-test.

745

746 **Figure 3. Antisense C9orf72 repeat expanded RNAs activate the PKR/eIF2 α pathway**
747 **independent of DPR proteins.**

748 **(A)** (Top) Schematic illustration of (C₄G₂)75 repeats without the human intronic sequences. 3 \times
749 protein tags were included at the C- terminus of the repeats to monitor the DPR proteins in
750 each frame. (Bottom) Schematic illustration of antisense (C₄G₂)108RO repeats with stop
751 codons inserted in every 12 repeats to prevent the translation of DPR proteins from all reading

752 frames. **(B)** Immunoblotting of DPR proteins in HEK293T cells expressing in₂(C₄G₂)₇₅,
753 (C₄G₂)₇₅, or 2 repeats. DPR protein levels were detected using anti-FLAG (frame with GP),
754 anti-MYC (frame with PR), and anti-HA (frame with PA). GAPDH was used as a loading
755 control. **(C)** mRNA levels were measured by quantitative qPCR in cell expressing in₂(C₄G₂)₇₅,
756 (C₄G₂)₇₅, or 2 repeats. Error bars represent S.D. (n=2). **(D-E)** Immunoblotting of p-PKR and
757 p-eIF2 α in HEK293T cells expressing in₂(C₄G₂)₇₅, (C₄G₂)₇₅, or 2 repeats. p-PKR (T446) and
758 p-eIF2 α (Ser51) were normalized to total PKR and eIF2 α respectively. GAPDH was used as a
759 loading control. Error bars represent S.D. (n=3 independent experiments). Statistical analyses
760 were performed using one-way ANOVA with Tukey's post hoc test.

761

762 **Figure 4. Antisense C9orf72 repeat expanded RNAs themselves induce stress granules**
763 **and lead to neuronal toxicity.**

764 **(A)** Representative images of FMRP staining in HEK293T cells expressing (C₄G₂)₁₀₈RO or 2
765 repeats. **(B)** Quantification of antisense foci positive cells with FMRP granules. Error bars
766 represent S.D. (n=180 cells/condition and three independent experiments). Statistical analyses
767 were performed using student's t-test. **(C)** Immunoblotting of PKR and p-eIF2 α (Ser51) in
768 HEK293T cells expressing (C₄G₂)₁₀₈RO together with control or PKR siRNA. GAPDH was
769 used as a loading control. **(D-E)** Representative images of FMRP staining in HEK293T cells
770 expressing (C₄G₂)₁₀₈ repeats together with either control or PKR siRNA **(D)**. Quantification
771 of antisense foci positive cells with FMRP granules. Error bars represent S.D. (n=150
772 cells/condition and three independent experiments) **(E)**. **(F)** Kaplan-Meier curves showing
773 increased risk of cell death in (C₄G₂)₁₀₈RO expressing neurons compared with 2 repeats.
774 Statistical analyses were performed using Mantel-Cox test (* p<0.05).

775

776 **Figure 5. Increased levels of phosphorylated PKR and eIF2 α in C9FTD/ALS patients.**

777 **(A)** Representative immunohistochemistry images of phosphorylated PKR staining in control
778 and C9FTD/ALS patient's frontal cortex (FCX) using anti-p-PKR (T446) (n=4 per genotype).
779 **(B-C)** Immunoblotting of p-eIF2 α in proteins extracted from control (C1-C6) and C9FTD/ALS
780 patient's frontal cortex (P1-P6). p-eIF2 α (Ser51) was normalized to total eIF2 α . GAPDH was
781 used as a loading control. Error bars represent S.D. (control n=6 and C9FTD/ALS n=6).
782 Statistical analyses were performed using unpaired student's t-test.

783

784 **Figure 6. Sense C9orf72 repeat expanded RNAs cannot activate the PKR/eIF2 α pathway.**

785 **(A-B)** Representative images **(A)** and Quantification of sense and antisense RNA foci in

786 HEK293T expressing (G₄C₂)₇₅ repeats together with either control ASOs or ASOs targeting
787 sense (G₄C₂) repeat expanded RNAs (**B**). Foci were detected by RNA FISH. Red, foci; blue,
788 DAPI. Error bars represent S.D. (n=90 cells/condition from three independent experiments).
789 Statistical analyses were performed using student's t-test. (**C-D**) Immunoblotting of p-PKR in
790 HEK293T cells expressing (G₄C₂)₇₅ or (G₄C₂)₂ repeats together with either control ASO or
791 ASOs targeting sense (G₄C₂) repeat expanded RNAs. Phosphorylated PKR levels were
792 detected using anti-p-PKR (phosphor T446) and normalized to total PKR. GAPDH was used
793 as a loading control. Error bars represent S.D. (n=3 independent experiments). Statistical
794 analyses were performed using unpaired student's t-test. (**E-F**) Representative images (**E**) and
795 Quantification (**F**) of sense and antisense RNA foci in HEK293T expressing (G₄C₂)₇₅ repeats
796 together with either control ASOs or ASOs targeting sense repeat expanded RNAs. Foci were
797 detected by RNA FISH. Red, foci; blue, DAPI. Error bars represent S.D. (n=90 cells/condition
798 and 3 independent experiments). Statistical analyses were performed using student's t-test. (**G-**
799 **H**) Immunoblotting of p-PKR and p-eIF2 α in HEK293T cells expressing (G₄C₂)₇₅ or (G₄C₂)₂
800 repeats together with either control ASO or ASOs targeting antisense (G₄C₂) repeat expanded
801 RNAs (**G**). P-PKR (T446) and p-eIF2 α (Ser51) were normalized to total PKR and eIF2 α
802 respectively (**H**). GAPDH was used as a loading control. Error bars represent S.D. (n=3
803 independent experiments). Statistical analyses were performed using one-way ANOVA with
804 Tukey's post hoc test.
805

ID	Primary Neuropathologic Diagnosis	Age at Onset	Age at Death	Sex
C1	Control	-	53	F
C2	Control	-	77	NA
C3	Control	-	43	F
C4	Control	-	57	M
C5	Control	-	72	F
C6	Control	-	57	F
P1	FTLD (C9 expansion)	58	71	M
P2	ALS (C9 expansion)	54	57	F
P3	FTLD (C9 expansion)	57	66	M
P4	FTLD (C9 expansion)	58	67	M
P5	FTLD (C9 expansion)	62	66	M
P6	ALS (C9 expansion)	-	69	NA

806 **Table 1. List of controls (C1-C6) and C9FTD/ALS patients (P1-P6) post-mortem tissues**
807 **used in this study.**

808
809

810 **Supplementary figures**

811

812 **Figure S1. C9orf72 C₄G₂ expanded repeats produce antisense DPR proteins in HEK293T**
813 **cells and primary neurons.**

814 Representative images of DPR protein staining in (A) HEK293T and (B) primary neurons
815 expressing in_(C₄G₂)₇₅ repeats. Red, GP, PA, and PR; blue, DAPI; MAP2, Magenta. (C)
816 Immunoblotting of DPR proteins in HEK293T expressing in_(C₄G₂)₇₅ repeats. Ponceau
817 staining was used as a loading control.

818

819 **Figure S2. C9orf72 C₄G₂ expanded repeats activate PKR/eIF2 α -dependent integrated**
820 **stress response in SH-SY5Y cells.**

821 (A) Immunoblotting of p-PERK in HEK293T cells expressing in_(C₄G₂)₇₅ or (C₄G₂)₂ repeats.
822 Phosphorylated PERK levels were quantified and normalized to total PERK. GAPDH was used
823 as a loading control. Error bars represent S.D. (n=2 independent experiments). Statistical
824 analyses were performed using student's t-test. (B-C) Immunoblotting of p-PKR and p-eIF2 α
825 in SH-SY5Y cells expressing (C₄G₂)₇₅ or (C₄G₂)₂ repeats. p-PKR (T446) and p-eIF2 α (Ser51)
826 were normalized to total PKR and eIF2 α respectively. GAPDH was used as a loading control.
827 Error bars represent S.D. (n=2 independent experiments). Statistical analyses were performed
828 using student's t-test. (D) Quantification of puromycin levels in HEK293T cells expressing
829 in_(C₄G₂)₇₅ or (C₄G₂)₂ repeats. The level of puromycin was normalized to GAPDH. Error
830 bars represent S.D. (n=3 independent experiments). Statistical analyses were performed using
831 student's t-test.

832

833 **Figure S3. Antisense DPR proteins do not activate PKR/eIF2 α -dependent integrated**
834 **stress response.**

835 (A-B) Representative images (A) and quantification (B) of p-eIF2 α staining in HEK293T cells
836 expressing in_(C₄G₂)₇₅, PR50, PA50, or GP80. Green, GP, PA, or PR; red, p-eIF2 α ; blue,
837 DAPI. Error bars represent S.D. (n=2 independent experiments). (C) Representative images of
838 antisense RNA foci in HEK293T cells expressing in_(C₄G₂)₇₅, (C₄G₂)₇₅ or (C₄G₂)_{108RO}
839 repeats. Foci were detected by RNA FISH. Red, foci; blue, DAPI. (D) Immunoblotting of DPR
840 proteins in HEK293T cells expressing in_(C₄G₂)₇₅, (C₄G₂)₇₅ and (C₄G₂)_{108RO} repeats. DPR

841 protein levels were detected using anti-PR and anti-GP. GAPDH was used as a loading control.
842 **(E)** Immunoblotting of PKR and p-eIF2 α (Ser51) in HEK293T cells expressing (C₄G₂)₁₀₈RO
843 together with control or PKR siRNA. PKR and p-eIF2 α (Ser51) were normalized to GAPDH
844 and total eIF2 α respectively. Error bars represent S.D. (n=2 independent experiments).
845 Statistical analyses were performed using student's t-test.

846

847 **Figure S4. C9orf72 sense G₄C₂ repeat expanded RNAs cannot activate the PKR/eIF2 α**
848 **pathway**

849 **(A)** Schematic illustration of the (G₄C₂)₇₅ repeat construct with 6 \times stop codons at the N-
850 terminus 3 \times protein tags at the C- terminus of the repeats to monitor the DPR proteins in each
851 frame. **(B-C)** Immunoblotting of p-PKR and p-eIF2 α in HEK293T cells expressing (G₄C₂)₇₅
852 or (G₄C₂)₂ repeats. p-PKR (T446) and p-eIF2 α (Ser51) were normalized to total PKR and
853 eIF2 α respectively. GAPDH was used as a loading control. Error bars represent S.D. (n=2
854 independent experiments). Statistical analyses were performed using student's t-test. **(D)**
855 Representative images of sense and antisense RNA foci in HEK293T cells expressing
856 (G₄C₂)₇₅. Foci were detected by RNA FISH. Red, foci; blue, DAPI. **(E)** Quantification of sense
857 RNA foci in HEK293T expressing (G₄C₂)₇₅ together with either control ASO or ASOs
858 targeting sense (G₄C₂) repeat expanded RNAs. Error bars represent S.D. (n=80-100
859 cells/condition from 3 independent experiments). **(F)** Immunoblotting of p-eIF2 α in HEK293T
860 cells expressing (G₄C₂)₇₅ or (G₄C₂)₂ repeats together with either control ASO or ASOs
861 targeting sense (G₄C₂) repeat expanded RNAs. **(G)** p-eIF2 α (Ser51) was normalized to total
862 eIF2 α . GAPDH was used as a loading control. Error bars represent S.D. (n=3 independent
863 experiments).

864




Figure 1




Figure 2










Figure 3

A**B****C****D****E****F****Figure 4**






Figure 5






Figure 6




Supplementary Figure 2


A




B




C









D



E



Supplementary Figure 3

A**B****C****D****E****F****G**